Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Alkermes ( (ALKS) ) just unveiled an announcement.
On November 12, 2025, Alkermes announced positive topline results from its Vibrance-2 phase 2 study, which evaluated the safety and efficacy of alixorexton in patients with narcolepsy type 2. The study demonstrated that alixorexton, a novel oral orexin 2 receptor agonist, met its dual primary endpoints by significantly improving wakefulness and reducing excessive daytime sleepiness compared to placebo. These results support the advancement of alixorexton to phase 3 trials, marking a significant milestone for the narcolepsy patient community and Alkermes’ development program.
The most recent analyst rating on (ALKS) stock is a Buy with a $44.00 price target. To see the full list of analyst forecasts on Alkermes stock, see the ALKS Stock Forecast page.
Spark’s Take on ALKS Stock
According to Spark, TipRanks’ AI Analyst, ALKS is a Outperform.
Alkermes’ overall stock score reflects strong financial performance and a positive outlook from the recent earnings call, which highlighted significant revenue growth and strategic acquisitions. While technical indicators show mixed signals, the company’s reasonable valuation and strategic initiatives support a solid investment case.
To see Spark’s full report on ALKS stock, click here.
More about Alkermes
Alkermes plc is a global biopharmaceutical company focused on developing innovative medicines in the field of neuroscience. It has a portfolio of proprietary commercial products for treating alcohol dependence, opioid dependence, schizophrenia, and bipolar I disorder, along with a pipeline of clinical and preclinical candidates for neurological disorders such as narcolepsy and idiopathic hypersomnia. The company is headquartered in Ireland, with a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.
Average Trading Volume: 2,152,312
Technical Sentiment Signal: Strong Buy
Current Market Cap: $5.39B
Find detailed analytics on ALKS stock on TipRanks’ Stock Analysis page.